Schrödinger Reports Strong Q4 2025 Earnings with Strategic Transition to Hosted Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy SDGR?
Source: seekingalpha
- Significant Revenue Growth: Schrödinger reported total revenue of $256 million for 2025, reflecting a 23% increase despite challenges from tight pharma budgets and biotech capital markets, underscoring the company's strong market position in molecular discovery.
- Software Business Performance: The software segment generated $199.5 million in revenue, an 11% increase year-over-year, while drug discovery revenue more than doubled to $56.4 million, indicating success in new product launches and customer expansion.
- Strategic Transition Progress: Schrödinger is shifting towards a primarily hosted licensing model, with expectations for 10% to 15% growth in annual contract value (ACV) for 2026, aiming for substantial growth in the coming years.
- Cost Control Effectiveness: Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, as the company implemented cost reduction initiatives, enhancing confidence in future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SDGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SDGR
Wall Street analysts forecast SDGR stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 12.060
Low
18.00
Averages
21.83
High
25.00
Current: 12.060
Low
18.00
Averages
21.83
High
25.00
About SDGR
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Schrödinger Reports Strong Q4 2025 Earnings with Strategic Transition to Hosted Model
- Significant Revenue Growth: Schrödinger reported total revenue of $256 million for 2025, reflecting a 23% increase despite challenges from tight pharma budgets and biotech capital markets, underscoring the company's strong market position in molecular discovery.
- Software Business Performance: The software segment generated $199.5 million in revenue, an 11% increase year-over-year, while drug discovery revenue more than doubled to $56.4 million, indicating success in new product launches and customer expansion.
- Strategic Transition Progress: Schrödinger is shifting towards a primarily hosted licensing model, with expectations for 10% to 15% growth in annual contract value (ACV) for 2026, aiming for substantial growth in the coming years.
- Cost Control Effectiveness: Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, as the company implemented cost reduction initiatives, enhancing confidence in future profitability.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On February 13, 2026, Schrödinger granted non-statutory stock options to purchase 9,600 shares at an exercise price of $11.40 per share, aligning with the closing price, aimed at attracting top talent to the company.
- Restricted Stock Units: The company also awarded 18,250 restricted stock units (RSUs) to eight new employees, conducted under the 2021 Inducement Equity Incentive Plan, reflecting the company's commitment to incentivizing new hires.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after 12 months of continuous service, followed by monthly or yearly installments, ensuring employee retention and enhancing company stability.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial sectors, showcasing strong market competitiveness and technological prowess.
See More
11 Stocks That Have Plummeted and Appear to Be Good Investment Opportunities
- Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
- Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued amidst the market downturn.
See More
Salesforce Shares and 10 Other Stocks That Have Plummeted and Appear to Be Good Investments
Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued following market crashes.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
Schrödinger Reports Strong Q4 2025 Earnings with Strategic Transition to Hosted Model
- Significant Revenue Growth: Schrödinger reported total revenue of $256 million for 2025, reflecting a 23% increase despite challenges from tight pharma budgets and biotech capital markets, underscoring the company's strong market position in molecular discovery.
- Software Business Performance: The software segment generated $199.5 million in revenue, an 11% increase year-over-year, while drug discovery revenue more than doubled to $56.4 million, indicating success in new product launches and customer expansion.
- Strategic Transition Progress: Schrödinger is shifting towards a primarily hosted licensing model, with expectations for 10% to 15% growth in annual contract value (ACV) for 2026, aiming for substantial growth in the coming years.
- Cost Control Effectiveness: Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, as the company implemented cost reduction initiatives, enhancing confidence in future profitability.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On February 13, 2026, Schrödinger granted non-statutory stock options to purchase 9,600 shares at an exercise price of $11.40 per share, aligning with the closing price, aimed at attracting top talent to the company.
- Restricted Stock Units: The company also awarded 18,250 restricted stock units (RSUs) to eight new employees, conducted under the 2021 Inducement Equity Incentive Plan, reflecting the company's commitment to incentivizing new hires.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after 12 months of continuous service, followed by monthly or yearly installments, ensuring employee retention and enhancing company stability.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial sectors, showcasing strong market competitiveness and technological prowess.
See More
11 Stocks That Have Plummeted and Appear to Be Good Investment Opportunities
- Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
- Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued amidst the market downturn.
See More
Salesforce Shares and 10 Other Stocks That Have Plummeted and Appear to Be Good Investments
Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued following market crashes.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
